PT-141 (Bremelanotide)

Evidence Anchor

BioHarmony 5.4/10

PT-141 lands at caution because it pairs the best evidence base in the peptide world with a modest payoff and a heavy nausea burden. If you are a premenopausal woman with diagnosed low desire who wants the one FDA-approved option, or someone who did not respond to a PDE5 inhibitor alone and wants a central mechanism to stack, it is a reasonable, evidence-backed choice, provided you can tolerate nausea and have no cardiovascular contraindication. If you expect a dramatic libido switch, the effect is small, and the satisfying-events endpoint was flat, per Spielmans 2021. The most underrated point: melanotan II is pharmacologically stronger for libido. ✅ Best for: Premenopausal women with diagnosed hypoactive sexual desire disorder who want the only approved drug option. Men or women who did not respond to Viagra-type drugs alone and want to add a central, desire-driven mechanism. People whose problem is genuinely desire rather than blood flow. Occasional, on-demand users who can tolerate nausea and will dose before sleep. Anyone who can confirm normal blood pressure, rule out cardiovascular disease, and obtain pharmaceutical-grade material with a certificate of analysis. ❌ Avoid if: You have uncontrolled high blood pressure or known cardiovascular disease, both absolute contraindications because each dose raises blood pressure. You take oral naltrexone, which PT-141 can render less effective by slowing gut absorption, per the Vyleesi label. You are pregnant or breastfeeding. You have a personal or family history of melanoma or many atypical moles, given melanocortin-1 activation. You want a reliable, strong effect, since a large minority do not respond. You cannot verify source quality, because contaminated research-chemical peptides are a documented risk.

Read the full BioHarmony report

My score and my verdict: one signal of three, never the whole answer.